Eliminating Silos in the Drug Delivery Value Chain
In the rapidly evolving landscape of drug delivery, breaking down silos in the drug delivery ecosystem has become crucial for ensuring efficiency and successful innovation of drug products.
GRAM is pushing the boundaries of what is possible in the pharmaceutical industry through our partnership with LTS, paving the way toward collaborative transparency in non-exclusive relationships. The collaboration leverages novel technology, particularly the filling of 10mL+ cartridges, to transform a specialized innovation into an accessible product. Through this partnership, GRAM has become an expert on the primary containers utilized in the Sorrel™ device. At the same time, LTS has gained valuable insights, facilitating an environment rich in industry knowledge and normalizing large volume, on-body delivery systems (LV OBDS).
By eliminating silos within the primary container ecosystem, we simplify decision-making processes that propel both capital investments and R&D projects forward. More than technical efficiency, this partnership is about making life easier for our clients. We offer solutions for vial or cartridge-based on-body injectors across various volumes through collaboration. Our streamlined communication leads to faster decisions and minimizes delays often resulting from poor inter-company coordination.
Critical decisions made at the incorrect time dramatically affect the product development timeline. Device developers must understand the needs of the market. For example, will a pharmaceutical company ever require a large volume primary container, and when will fill/finish providers commit to filling them? Device companies must also bring clinically available large-volume platforms to market. Partnerships like the one with GRAM and LTS collaboratively tackle pressing questions with enhanced communication across the drug delivery value chain (pharmaceutical companies, primary container providers, drug delivery systems, and CDMOs).
Through earlier collaboration, we can decide on the timing for technology investments, determine optimal volumes and configurations, and strive to standardize OBDS primary container solutions where feasible. Ultimately, our collaborative approach fosters decisive action and progress, guided by input from the entire value chain. Our shared objective is to anticipate future patient needs through seamless collaboration and innovation.
Learn more about our drug delivery partnerships and connect with our team.